IRS2 and colorectal carcinoma: miR-30a targets insulin receptor substrate (IRS2), phosphoinositide 3-kinase catalytic subunit delta (PIK3CD), and integrin β3 in CRC to inhibit proliferation, migration, and invasion24,71,77.